Correlation of the treatment sensitivity of patient-derived organoids with treatment outcomes in patients with head and neck cancer (SOTO): protocol for a prospective observational study

• Published in: BMJ open Vol. 14; no. 10; p. e084176
• Main Authors: Vasiliadou, Ifigenia, Cattaneo, Christiana, Chan, Phoebe Yuen Ka, Henley-Smith, Rhonda, Gregson-Williams, Harry, Collins, Lisette, Wojewodka, Gabriella, Guerrero-Urbano, Teresa, Jeannon, Jean-Pierre, Connor, Steve, Davis, Jessica, Pasto, Anna, Mustapha, Rami, Ng, Tony, Kong, Anthony
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 10-10-2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Biobanks; Biomarkers; Biomarkers, Tumor; Biopsy; Breast cancer; Cancer therapies; Chemotherapy; Clinical trials; Colorectal cancer; Disease; Drug resistance; Endoscopy; Head & neck cancer; Head & neck tumours; Head and Neck Neoplasms - pathology; Head and Neck Neoplasms - therapy; Human papillomavirus; Humans; Medical research; Metastasis; Mutation; Observational Studies as Topic; Oncology; Oral medicine; Organoids; Patients; Prospective Studies; Protocol; Protocols & guidelines; Radiation therapy; Research Design; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - pathology; Squamous Cell Carcinoma of Head and Neck - therapy; Stem cells; Treatment Outcome; Tumors; Oral medicine; Protocols & guidelines; Head & neck tumours
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2024-084176

IntroductionOrganoids have been successfully used in several areas of cancer research and large living biobanks of patient-derived organoids (PDOs) have been developed from various malignancies. The characteristics of the original tumour tissue such as mutation signatures, phenotype and genetic diversity are well preserved in organoids, thus showing promising results for the use of this model in translational research. In this study, we aim to assess whether we can generate PDOs from head and neck squamous cell carcinoma (HNSCC) samples and whether PDOs can be used to predict treatment sensitivity in HNSCC patients as well as to explore potential biomarkers.Methods and analysisThis is a prospective observational study at a single centre (Guy’s and St Thomas’ NHS Foundation Trust) to generate PDOs from patients’ samples to assess treatment response and to correlate with patients’ treatment outcomes. Patients will be included if they are diagnosed with HNSCC undergoing curative treatment (primary surgery or radiotherapy) or presenting with recurrent or metastatic cancers and they will be categorised into three groups (cohort 1: primary surgery, cohort 2: primary radiotherapy and cohort 3: recurrent/metastatic disease). Research tumour samples will be collected and processed into PDOs and chemosensitivity/radiosensitivity will be assessed using established methods. Moreover, blood and other biological samples (eg, saliva) will be collected at different time intervals during treatment and will be processed in the laboratory for plasma and peripheral blood mononuclear cell (PBMC) isolation. Plasma and saliva will be used for circulating tumour DNA analysis and PBMC will be stored for assessment of the peripheral immune characteristics of the patients as well as to perform co-culture experiments with PDOs. SOTO study (correlation of the treatment Sensitivity of patient-derived Organoids with Treatment Outcomes in patients with head and neck cancer) uses the collaboration of several specialties in head and neck cancer and has the potential to explore multiple areas of research with the aim of offering a valid and effective approach to personalised medicine for cancer patients.Ethics and disseminationThis study was approved by North West-Greater Manchester South Research Ethics Committee (REC Ref: 22/NW/0023) on 21 March 2022. An informed consent will be obtained from all participants prior to inclusion in the study. Results will be disseminated via peer-reviewed publications and presentations at international conferences.Trial registration numberNCT05400239.